Learn what retatrutide is, how its triple agonist action on GLP‑1, GIP, and glucagon receptors works, and why early clinical trials show up to 24% weight loss and major improvements in blood sugar control.
Discover how tirzepatide’s dual GIP/GLP‑1 receptor agonism is transforming peptide therapy for type 2 diabetes, delivering unprecedented HbA1c reductions, significant weight loss, and broader metabolic benefits compared to traditional GLP‑1 drugs.